We are live on ! Find out more
INZY

Inozyme Pharma
INZY

Delisted

INZY was delisted on the 30th of June, 2025.

Back to rankings

47 hedge funds and large institutions have $149M invested in Inozyme Pharma in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 18 increasing their positions, 14 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

110% more capital invested

Capital invested by funds: $71.2M → $149M (+$78.2M)

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

29% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 14

5.13% more ownership

Funds ownership: 73.54% → 78.68% (+5.1%)

6% less funds holding

Funds holding: 50 → 47 (-3)

13% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 15

Holders
47
Holders Change
-3
Holders Change %
-6%
% of All Funds
0.79%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
13
Increased
18
Reduced
14
Closed
15
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DTC
Deep Track Capital
Connecticut
+$14.1M
2
VA
VR Adviser
New York
+$11.8M
3
SI
Sofinnova Investments
California
+$7.08M
4
RSCM
Rock Springs Capital Management
Maryland
+$6.29M
5
SFM
Sphera Funds Management
Israel
+$5.07M

Top Sellers

Rank Fund Capital Flow
1
SCM
Suvretta Capital Management
New York
-$4.14M
2
BlackRock
BlackRock
New York
-$1.95M
3
JP Morgan Chase
JP Morgan Chase
New York
-$1.35M
4
State Street
State Street
Massachusetts
-$609K
5
Northern Trust
Northern Trust
Illinois
-$291K
Name Holding Trade Value Shares
Change 		Change in
Stake
SI
1
Sofinnova Investments
California
$17.4M +$7.08M +1,627,000 +80%
DTC
2
Deep Track Capital
Connecticut
$15.5M +$14.1M +3,250,000 New
VA
3
VR Adviser
New York
$12.9M +$11.8M +2,709,987 New
DM
4
Deerfield Management
New York
$12.9M +$1.53M +351,586 +15%
PBPIA
5
Pivotal bioVenture Partners Investment Advisor
California
$12.7M +$4.65M +1,070,000 +67%
RSCM
6
Rock Springs Capital Management
Maryland
$12.6M +$6.29M +1,446,861 +121%
Adage Capital Partners
7
Adage Capital Partners
Massachusetts
$12.1M +$3.48M +800,000 +46%
NMC
8
NEA Management Company
Maryland
$10.5M – – –
CA
9
CHI Advisors
New York
$9.7M +$4.97M +1,141,745 +128%
Vanguard Group
10
Vanguard Group
Pennsylvania
$6.46M +$3.76M +864,603 +177%
SFM
11
Sphera Funds Management
Israel
$5.56M +$5.07M +1,165,600 New
Janus Henderson Group
12
Janus Henderson Group
United Kingdom
$4.46M +$1.78M +409,193 +79%
MB
13
MPM BioImpact
Massachusetts
$3.17M +$1.61M +370,000 +125%
Fidelity Investments
14
Fidelity Investments
Massachusetts
$2.91M +$978 +225 +0%
BlackRock
15
BlackRock
New York
$2.05M -$1.95M -447,880 -51%
LCM
16
Laurion Capital Management
New York
$1.3M +$1.14M +261,800 +2,618%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$1.03M +$134K +30,918 +17%
Millennium Management
18
Millennium Management
New York
$826K +$753K +173,092 New
UOC
19
UBS O'Connor
Illinois
$817K +$745K +171,347 New
Citadel Advisors
20
Citadel Advisors
Florida
$577K +$98K +22,530 +23%
Renaissance Technologies
21
Renaissance Technologies
New York
$564K +$463K +106,400 +894%
BBA
22
Baker Bros. Advisors
New York
$510K – – –
Walleye Capital
23
Walleye Capital
New York
$484K +$441K +101,442 New
BCM
24
Bridgeway Capital Management
Texas
$417K +$130K +30,000 +52%
OMC
25
Overbrook Management Corp
New York
$331K +$229K +52,600 +314%
1
2 3

INZY Hedge Fund Activity: Q2 2022 in Review

47 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q2 2022, worth a combined $149M — up 110% from $71.2M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of INZY and 13 opened new positions — a net loss of 2 holders — while 14 trimmed existing stakes and 18 added.

The largest buyer was Deep Track Capital, opening a new position worth an estimated $14.1M. The largest seller was Suvretta Capital Management, exiting entirely with an estimated $4.14M sold.

  • 47 institutional investors held Inozyme Pharma (INZY) as of Q2 2022, down from 50 in Q1 2022.
  • Funds reported $149M of Inozyme Pharma stock for Q2 2022, up 110% quarter-over-quarter.
  • 13 funds opened new Inozyme Pharma positions in Q2 2022 and 15 closed out, a net change of -2 holders.
  • The largest Inozyme Pharma buyer in Q2 2022 was Deep Track Capital, an estimated $14.1M added.
  • The largest Inozyme Pharma seller in Q2 2022 was Suvretta Capital Management, an estimated $4.14M sold.

Based on aggregated 13F filings for Q2 2022.